Recon: FDA says Lilly’s tirzepatide shortage is resolved; Merck’s HIV therapy achieves success in pair of Phase 3 trials
ReconJason Scott
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States